Debt-to-equity in % of RELMADA THERAPEUTICS, INC. from Q3 2014 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Relmada Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q3 2014 to Q3 2025.
  • Relmada Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 31.3 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 31.3 Sep 30, 2025
Q2 2025 23.7 Jun 30, 2025
Q4 2019 6.73 +191 Dec 31, 2019
Q3 2019 59 +261 Sep 30, 2019
Q2 2019 2.01K +2.46K Jun 30, 2019
Q1 2019 -186 -1.58K -113% Mar 31, 2019
Q4 2018 -185 -382 -193% Dec 31, 2018
Q3 2018 -202 -283 -348% Sep 30, 2018
Q2 2018 -455 -501 -1094% Jun 30, 2018
Q1 2018 1.39K +1.35K +3198% Mar 31, 2018
Q4 2017 198 +163 +465% Dec 31, 2017
Q3 2017 81.2 +43.9 +118% Sep 30, 2017
Q2 2017 45.8 Jun 30, 2017
Q1 2017 42.2 Mar 31, 2017
Q4 2016 35 Dec 31, 2016
Q3 2016 37.3 Sep 30, 2016
Q2 2015 -2.44K Jun 30, 2015
Q1 2015 -875 Mar 31, 2015
Q4 2014 -411 Dec 31, 2014
Q3 2014 -217 Sep 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.